Adult Clinical Trials

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Genomically-Guided Treatment Trial in Brain Metastases

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)

OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Protocol NRG-BR009, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) (NCT05879926)

NRG-BR008, "A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer” (HERO)

Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (Aspen)

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

 A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

A211801 - BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation

EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)

A RANDOMIZED TRIAL ADDRESSING CANCER-RELATED FINANCIAL HARDSHIP THROUGH
DELIVERY OF A PROACTIVE FINANCIAL NAVIGATION INTERVENTION (CREDIT)

Blinded Reference Set for Multicancer Early Detection Blood Tests

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH
ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)

DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

REACHING RURAL CANCER SURVIVORS WHO SMOKE USING TEXT-BASED CESSATION INTERVENTIONS

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

S2205, ICE COMPRESS: RANDOMIZED TRIAL OF LIMB CRYOCOMPRESSION VERSUS CONTINUOUS COMPRESSION VERSUS LOW CYCLIC COMPRESSION FOR THE PREVENTION OF TAXANE-INDUCED PERIPHERAL NEUROPATHY
 

Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

URCC-19075 “Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)”

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.

A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients

A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial

A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer

A Randomized Phase III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial.

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

 EA2212, “A Randomized Phase II Study of Perioperative Atezolizumab  +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer”

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)

NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

NRG-GU011, A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

NRG-GU013, The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer

PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)

SWOG - S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).”

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] 

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS

NRG-GY033, “A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor” (NCT 06169124)

A RANDOMIZED PHASE 2/3 STUDY OF OLAPARIB PLUS TEMOZOLOMIDE VERSUS INVESTIGATOR’S CHOICE FOR THE TREATMENT OF PATIENTS WITH ADVANCED UTERINE LEIOMYOSARCOMA AFTER PROGRESSION ON PRIOR CHEMOTHERAPY

A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III), a prospective phase II treatment trial

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing    

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

The National Myelodysplastic Syndromes (MDS) Study

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI):  A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

 RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC:  RAPTOR trial

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A substudy of ALCHEMIST A151216

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Non-Chemotherapy Treatment (ramucirumab plus pembrolizumab) or Usual Care forAdvanced Non-Small Cell Lung Cancer Following Immunotherapy

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: E4512 and EA5142

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

EAQ211: Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors

 A Randomized Phase II trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

COG-AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Patients must be 5 to 60 years of age at the time of enrollment.

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

URCC-19075 “Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)”

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Genomically-Guided Treatment Trial in Brain Metastases

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS

A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers

Cancer Moonshot Biobank Research Protocol

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

S2209 A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-drug Induction Regimens Followed by Double- or Single-Agent Maintenance

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS

PHASE 2 TRIAL OF FULVESTRANT AND BINIMETINIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER WITH A FRAMESHIFT OR NONSENSE MUTATION OR GENOMIC DELETION IN NF1

A RANDOMIZED TRIAL OF SELUMETINIB AND OLAPARIB
OR SELUMETINIB ALONE IN PATIENTS WITH RECURRENT OR
PERSISTENT RAS PATHWAY MUTANT OVARIAN AND ENDOMETRIAL
CANCERS

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory
Participants with AKT-Altered Advanced Non-Breast Solid Tumors

A COMBOMATCH TREATMENT TRIAL: FOLFOX IN COMBINATION WITH BINIMETINIB AS 2ND LINE THERAPY FOR PATIENTS WITH ADVANCED BILIARY TRACT CANCERS WITH MAPK PATHWAY ALTERATIONS

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

COG AOST2031

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Patients must be < 50 years at the time of enrollment

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Symptomatic Brain Metastases

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA

S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study.